title: Lactic acid bacteria as oral delivery systems for biomolecules.
abstract: Lactic acid bacteria (LAB) have become increasingly studied over the last two decades as potential delivery systems for various biological molecules to the gastrointestinal tract. This article presents an overview of characteristics of LAB as delivery systems and of the applications which have already been developed. The majority of LAB strains are able to survive the intestinal passage and some are also able to persist and colonize the intestine. Several strains were in fact described as members of the human commensal flora. They can interact with their host and are able to deliver large molecular weight biomolecules across the epithelium via M-cells or dendritic cells. The most widely applied LAB species has been Lactococcus lactis; however species from genus Lactobacillus are gaining popularity and the first examples from genus Bifidobacterium are starting to emerge. Bacteria are mostly applied live and enable continuous delivery of the biomolecules. However, killed bacteria (e.g. gram-positive enhancer matrix), with bound biomolecules or as adjuvants, are also being developed. The techniques for genetic modification of LAB are well known. This review focuses on the delivery of recombinant proteins and DNA, which can cause either local or systemic effects. We divide recombinant proteins into antigens and therapeutic proteins. Delivery of antigens for the purpose of vaccination represents the most abundant application with numerous successful demonstrations of the efficacy on the animal model. Therapeutic proteins have mostly been developed for the treatment of the inflammatory bowel disease, by the delivery of anti-inflammatory cytokines, or downregulation of proinflammatory cytokines. Delivery of allergens for the modulation of allergic disorders represents the second most popular application of therapeutic proteins. The delivery of DNA by LAB was demonstrated and offers exciting opportunities, especially as a vaccine. New discoveries may eventually lead to the transition of LAB as delivery systems in clinical practice.
authors.affiliation: Department of Biotechnology, Jozef Stefan Institute, Ljubljana, Slovenia.
authors.forename: A
authors.initials: A
authors.lastname: Berlec
authors.forename: M
authors.initials: M
authors.lastname: Ravnikar
authors.forename: B
authors.initials: B
authors.lastname: Strukelj
mesh_terms: D001419:Bacteria / Q000378:metabolism*; D001685:Biological Factors / Q000008:administration & dosage* / Q000627:therapeutic use; D004247:DNA / Q000008:administration & dosage / Q000627:therapeutic use; D016503:Drug Delivery Systems; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007422:Intestines / Q000382:microbiology; D019344:Lactic Acid / Q000378:metabolism*; D007778:Lactobacillus / Q000378:metabolism; D017045:Lactococcus / Q000378:metabolism; D011506:Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D014612:Vaccines / Q000008:administration & dosage
chemical_list: D001685:Biological Factors; D011506:Proteins; D014612:Vaccines; D019344:Lactic Acid; D004247:DNA